Frontlight ResearchEarly access
Active, not recruitingNo phase
Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 200 people, planned
- Started
- 1 Nov 2024
- Expected to end
- 30 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Blue star MAX-5 spectacle lens
- Single-vision spectacle lens
- Record updated
- 12 March 2026
Who can take part
- Age
- 8 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 8 to 11 years
- Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -6.00 to -0.50 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.50 D
- Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
- The intraocular pressure of 10 to 21mmHg
- Volunteer to participate in this clinical trial with signature of the informed consent form
Who cannot take part
- Participation of the drug clinical trial within three month and the device clinical trial within one month
- Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursingproducts), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
- History of eye injury or intraocular surgery
- Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
- Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
- Clinically abnormal slit-lamp findings
- Abnormal fundus examination
- Only one eye meets the inclusion criteria
- Unable to have regular follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this randomised controlled clinical trial is to compare the effects of a new type of concentric columnar microstructure lens and single-vision spectacle lenses on myopia progression in Chinese children aged 8-11 years with refractive error ranging from -0.50D to -6.00D. Participants will wear spectacles and receive follow-up examinations every half year.
The 2 groups in the trial
- InterventionTreatment being tested
Blue star MAX-5 spectacle lens
Treatment: Blue star MAX-5 spectacle lens
- ControlExisting treatment, for comparison
Single-vision spectacle lens
Treatment: Single-vision spectacle lens
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Blue Star MAX-5 Lenses in Mvopia Control: A Randomized Controlled Clinical Trial
- Record updated
- 12 March 2026